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Abstract
Sumoylation is a recently described post-translational modification and only a few sumoylated
neurotransmitter receptors are known. Through the present studies, we discovered that
serotonin1A receptors (5-HT1A-Rs) can be sumoylated by SUMO1 (Small-Ubiquitin-related
modifier 1) protein. The SUMO1-5-HT1A-R is ～ 55kD, is located in the membrane fraction, but
not the cytosol, and is distributed in all of the brain regions expressing 5-HT1A-Rs examined.
Acute stimulation of 5-HT1A-Rs significantly increased SUMO1-5-HT1A-R in rat hypothalamus.
Pre-treatment with estradiol for 2 days, which causes a partial desensitization of 5-HT1A-R
signaling, potentiated agonistinduced increases in SUMO1-5-HT1A-Rs in the hypothalamus of
ovariectomized rats. Using discontinuous gradient centrifugation followed by digitonin treatment,
we found that the majority of SUMO1-5-HT1A-Rs is co-localized with endoplasmic-reticulum and
trans-Golgi-network markers. Although a small proportion of SUMO1-5-HT1A-Rs are located in
the detergent resistant microdomain (DRM) that contain active G-protein coupled receptors, their
distribution was different from that of the Gαz protein that couples to the receptors. These data
suggest that the SUMO1-5-HT1A-Rs are an inactive form of 5-HT1A-Rs, a finding further
supported by results showing minimal 5-HT1A-R agonist binding to SUMO1-5-HT1A-Rs.
Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R
agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin). Together, these data suggest that
sumoylation of 5-HT1A-Rs may be related to 5-HT1A-R trafficking and internalization, which may
contribute to 5-HT1A-R desensitization. Since 5-HT1A-Rs play an important role in mood
regulation, the present results significantly impact on the understanding of the pathogenesis of
affective disorders and development of better therapeutic approaches for these diseases.
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Introduction
Sumoylation is a relatively novel post-translational protein modification in which a small-
ubiquitin-related modifier (SUMO) protein covalently binds to target proteins. SUMO
proteins, including SUMO1, SUMO2 and SUMO 3, are small proteins with 95–101 amino
acids (Wilkinson and Henley, 2010). Sumoylation alters the function of the target proteins
depending on the target proteins and cell type in which it occurs (Gareau and Lima, 2010;
Geiss-Friedlander and Melchior, 2007; Wilkinson and Henley, 2010). The majority of
sumoylated proteins identified so far are transcription factors, in which sumoylation either
facilitates their translocation to the nucleus or regulates their function in the nucleus.
However, increasing evidence demonstrates that sumoylation of extranuclear proteins play
important roles in the modulation of protein-protein interactions and consequently regulates
the stability and function of these proteins (Andreou and Tavernarakis, 2009; Martin et al.,
2007; Palmer et al., 2011; Wilkinson et al., 2010). As a result, protein sumoylation is
involved in the regulation of several cellular processes, such as cell signaling, mitochondrial
function and regulation of cell morphology . Furthermore, growing evidence demonstrates
that the sumoylation of extra-nuclear proteins is related to the regulation of neuronal
development and neuronal function (Anderson et al., 2009; Martin et al., 2007; Scheschonka
et al., 2007). Studies have revealed that sumoylation is involved in the regulation of synaptic
activity, such as altering neurotransmitter release, and the functioning of post-synaptic
receptors, ion channels and transporters (Craig and Henley, 2012; Rusakov et al., 2011).
Although this evidence suggests that sumoylation may play an important role in the
regulation of neuronal function, the effects of sumoylation in central nervous system are not
well understood. To date, relatively few proteins in neurons have been identified as
substrates for sumoylation, especially extra-nuclear proteins. For example, only two G-
protein-coupled receptors (GPCR), cannabinoid receptor 1 (CB1) and metabotropic
glutamate receptor 8 (mGluR)8, have been identified as substrates for sumoylation (Enz,
2012; Gowran et al., 2009). Gowran et al found that agonist treatment decreased
sumoylation of CB1 (Gowran et al., 2009). Although studies have demonstrated the
sumoylation of mGluR8 (Dutting et al., 2011; Mao et al., 2011), no data are available
regarding the effects of sumoylation on the function of the receptors. On the other hand,
several studies on ionotropic kainate receptors demonstrate that agonist-stimulation induces
sumoylation of kainate receptor subunits GluK2 (GluR6), resulting in reduced function of
the receptors and increased receptor endocytosis (Chamberlain et al., 2012; Konopacki et al.,
2011). Here, we report, for the first time, that another GPCR, serotonin1A receptor (5-
HT1A-R) can be sumoylated.
5-HT1A-Rs play important roles in numerous neurological and behavioral processes,
including mood regulation and the pathogenesis of anxiety and depression (Akimova et al.,
2009). Mice constitutively lacking 5-HT1A-Rs are more anxious (Gross et al., 2000) and 5-
HT1A-R agonists are used as anxiolytic drugs. Furthermore, desensitization of 5-HT1A-Rs is
critical for the therapeutic effects of antidepressants (Artigas et al., 2001; Blier and Abbott,
2001). Our recent studies demonstrated that estradiol facilitates the desensitization of 5-
HT1A-Rs in conjunction with the prototypical antidepressant, fluoxetine (Li et al., 2012).
Thus, understanding the regulation of 5-HT1A-Rs will have a significant impact on our
understanding of the pathogenesis of anxiety disorders and depression and on the
development of better therapeutic approaches for affective disorders.
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5-HT1A-Rs are GPCRs that are coupled to the Gαi/o-protein family (Valdizan et al., 2010).
Our previous studies demonstrated that 5-HT1A-Rs in the hypothalamus mediating ACTH
and oxytocin release are coupled with Gαz protein, a member of the Gαi/o protein family
(Serres et al., 2000). Gαz protein and active 5-HT1A-Rs (Li et al., 2012; Renner et al., 2007),
like other GPCRs, are located in the detergent resistant microdomain (DRM). The DRM
contains GPCRs, G-proteins and other proteins associated with GPCR signaling, physically
bringing together these components for GPCR signaling. On the other hand, proteins
dynamically move in and out of the DRM based on the activity of GPCR signaling (Allen et
al., 2007; Chini and Parenti, 2004). Previous studies reported regulation of 5-HT1A-Rs by
post-translation modifications, such as phosphorylation, glycosylation and palmitoylation
(Papoucheva et al., 2004). In the present study, we characterized the sumoylation of 5-
HT1A-Rs and the possible role of sumoylation in receptor trafficking by identifying the
effects of sumoylation on subcellular location of 5-HT1A-Rs and the responses to agonist
stimulation and treatment with estradiol.
Methods
Animals
Adult female Sprague-Dawley rats (225- 250g) purchased from Harlan Laboratories
(Indianapolis, IN) were housed two per cage in a temperature-, humidity-, and light-
controlled room (12 h light/dark cycles). Food and water were available ad libitum. All
procedures were conducted in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and as approved by the University of Kansas
Institutional Animal Care and Use Committees.
Effect of treatment with estradiol and/or fluoxetine for 2 days on the 8-OH-DPAT-induced
increase in sumoylation of 5-HT1A-Rs in the hypothalamus
As we previously described (Li et al., 2012), ovariectomized female rats were injected with
estradiol benzoate (EB) (10 µg/kg, 0.4ml/kg, sc) and/or fluoxetine (10 mg/kg, sc) for 2 days.
Eighteen hours after the last injection, rats were injected with saline or 8-OH-DPAT, 200µg/
kg, sc and were then decapitated 15 min after the injection. The brains were collected and
stored at −80°C until use. The hypothalamus was dissected and prepared as described below.
Three hundred micrograms of membrane protein were used for immunoprecipitation with
the SUMO1 antibody followed by immunoblotting with 5-HT1A-R antibody.
Brain tissue preparation
was conducted as previously described (Li et al., 2012): Briefly, brain tissue was
homogenized in 10 volume (v/w) of homogenate buffer (50 mM Tris, 150 mM NaCl and
10% sucrose, pH 7.4, containing 20 mM N-Ethylmaleimide (NEM), 1:100 diluted protease
inhibitor cocktail, phosphatase inhibitor cocktail I and II (Sigma) using a homogenizer.
After centrifugation at 25,000xg, 4°C for 1 hour, the supernatant was collected as the
cytosolic fraction. The pellets were sonicated in solubilization buffer (20 mM Tris, pH 8, 1
mM EDTA, 100 mM NaCl, 1% sodium cholate containing 20 mM NEM, 1:100 diluted
protease inhibitor cocktail, phosphatase inhibitor cocktail I and II) and then were shaken
vigorously for 1 hr at 4°C. After a centrifugation at 25,000xg, 4°C for 1 hour, the
supernatant was collected as the membrane fraction. Protein concentration of the samples
was measured using BCA assay (Thermo Scientific Inc, Rockford IL).
Isolation of DRM from cortex tissue
To determine whether sumoylated 5-HT1A-Rs are located in the DRM, we isolated DRM
from the cortex using a protocol described by Kumari and Francesconi (Kumari and
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Francesconi, 2011) with minor modification. Briefly, rat cortex was homogenized with a
homogenizer driven by an overhead-motor at 500 rpm for 25 strokes in 10 volume of
homogenate buffer (10 mM Tris–HCl, pH 7.4, 5 mM EDTA, 320 mM sucrose, 20mM
NEM, 1:100 dilution of protease inhibitor cocktail (Sigma) and phosphatase inhibitor II &
III cocktails (Sigma)). The homogenate was centrifuged at 800xg for 15 min at 4°C to
remove the nucleus and cell debris. The supernatant was then centrifuged at 30,000xg for 30
min at 4°C. The pellet was resuspended in 2.2 ml of extracting buffer (50 mM Tris–HCl, pH
7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100 (v/v), 20mM NEM, 1:100 dilution of
protease and phosphatase inhibitor cocktails) and was then incubated for 10 min in ice. Two
ml of the Triton X-100-treated homogenate was adjusted to a final concentration of 40%
sucrose with an 80% sucrose solution in extracting buffer. The 40% sucrose Triton X-100-
treated homogenate was placed on the bottom of a 13 ml centrifugation tube and was
overlaid with 6 ml of 30% sucrose on the top. Finally, 2 ml of 5% sucrose buffer was placed
on the top of 30% sucrose. The sucrose gradient was then centrifuged at 230,000x g, 4°C for
16 hours. After the centrifugation, 1 ml fractions were collected from top to bottom. To
solubilize the membrane protein, 0.1 ml of 10% sodium cholate was added to the fractions,
which were then sonicated and shaken for one hour at 4°C. The fractions were aliquoted and
stored in −80°C until use. The protein concentration of the fractions was measured using
Pierce BCA protein assay kit (Thermo Scientific Inc, Rockford IL). Ten and 300 µg of
protein were used for immunoblot and immunoprecipitation assays, respectively.
Subcellular fractionation of brain samples
Subcellular organelles were separated using a discontinuous OptiPrep gradient
centrifugation based on the manufacture’s protocol (http://www.axis-shield-density-
gradient-media.com/organelleindexes.htm, Application 05 and 22) with modification. The
rat brain regions were dissected and homogenized with 4 volumes of homogenate buffer
(0.32M sucrose, 1mM EDTA 10mM Tris-HCl pH 7.4, 20 mM NEM, 1/100 dilution of
protease and phosphatase inhibitors) using a Powergen 1000 (Fisher Scientific) homogenizer
at speed 5, 4°C for ～10 sec. After centrifugation at 1500x g, 4°C for 15 min, the supernatant
was used for discontinuous gradient centrifugation. Iodixanol (Optiprep, Sigma) was diluted
into 7.5, 10, 12.5, 15, 20, 25 and 30% with Diluent (0.25mM sucrose, 6mM EDTA 60mM
Tris-HCl pH 7.4, 20 mM NEM, 1/100 dilution of protease and phosphatase inhibitors). 1 ml
of each solution was under-layered from 7.5% to 30% sequentially in a 13 ml SW41
centrifuge tube. 1 ml of brain supernatant was layered on the 7.5% iodixanol solution and
centrifuged at 200,000xg (40,300 rpm) at 4°C for 3 hours in a SW41 rotor. After the
centrifugation, 0.5 ml fractions were collected from top to bottom of the tube. To solubilize
the membrane proteins, 50 µl 10% sodium cholate was added into each fraction. The
solution was sonicated at 25 Amp 3 times for 5 sec each with 5 sec intervals in ice and was
then shaken vigorously at 4°C for 1 hour. The solution was then aliquoted and stored in
−80°C until used for immunoblotting and immunoprecipitation of sumoylated 5-HT1A-Rs.
Digitonin treatment of the plasma membrane and the endoplasmic reticulum (ER) fractions
Digitonin binds to cholesterol, which shift the membranes containing high levels of
cholesterol, such as the plasma membrane and endosomes, to a higher density, whereas the
membrane compartments containing low cholesterol concentrations, such as ER and
lysosomes, display little or no shift by digitonin treatment. To confirm that the SUMO1-5-
HT1A-Rs are located in the trans-Golgi network (TGN), ER-Golgi intermediate
compartment (ERGIC) and ER, we treated hippocampal subcellular fractions containing the
ER and TGN with digitonin followed by a second discontinuous gradient centrifugation. The
subcellular fractions containing plasma membrane were used as a control for digitonin
treatment. The digitonin treatment protocol was modified from Castle JD (Castle, 2004).
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Hippocampal subcellular fractions (0.5 ml each) were obtained using gradient centrifugation
as described above. The distributions of 5-HT1A-R, Na+/K+ ATPase and calnexin were
identified using immunoblot assay (Fig.4). The fractions (#13 and #14) containing high
levels of Na+/K+ ATPase, a marker of plasma membrane and the fractions (#18 and #19)
containing high levels of calnexin, a ER marker, were pooled, respectively, and divided into
two samples (～0.5 ml/vial), which were treated with vehicle or digitonin (1.7 mg/ml) for 15
min at 4°C. The digitonin and vehicle- treated fractions were then subjected to a second
discontinue gradient centrifugation. Fraction 13 & 14 were loaded on the top of a gradient
with 17.5 –35% iodixanal (0.5 ml each of 17.5, 20, 22.5, 25, 27.5, 30, 32.5 and 35%
iodixanol), whereas the fractions 18 & 19 were loaded on a discontinue gradient with 25–
50% iodixanol (0.5 ml each of 25, 27.5, 30, 32.5, 35, 37.5,40, 45 and 50% iodixanol). After
centrifugation at 230,000xg, at 4°C for 3 hours in a MLS 50 rotor, the fractions (0.25 ml
each) were collected from the top to the bottom of the centrifuge tubes. The proteins in the
fractions were solubilized by adding 25µl of 10% sodium cholate and shaken vigorously for
1 hour. The fractions were then aliquoted and stored in −80°C until use for immunoblot and
immunoprecipitation.
3H-8-OH-DPAT binding of cortex subcellular fractions
To determine whether the sumoylated 5-HT1A-R are active, we determined the agonist
binding activity of 5-HT1A-Rs in the subcellular fractions of cortical tissue. Cortex
subcellular fractions were produced by discontinuous centrifugation as described above with
slight modification. The tissue was homogenized and centrifuged without adding inhibitors
because inhibitors disrupt the receptor binding activity. The discontinuous gradient
centrifugation was performed as described in the subcellular fraction section except 10, 15,
17.5, 20, 22.5, 25, 27.5, 30, 35 and 40% Optiprep was used. After centrifugation, 1 ml
fractions were collected from top to bottom. To determine the correlation between
sumoylated 5-HT1A-R and binding activity, 0.5 ml aliquots of each fraction were added to
50µl 10% sodium cholate containing 200 mM NEM, 1/10 dilution of protease and
phosphatase inhibitors immediately to prevent protein degradation. The aliquot was then
sonicated and shaken to solubilize membrane proteins as described above and stored in
−80°C until used for immunoprecipitation and immunoblotting. The remaining 0.5 ml
aliquot of each fraction was used for a 3H-8-OH-DPAT binding assay immediately after
collection of the fractions.
3H-8-OH-DPAT binding was conducted as previously described (Li et al., 1994).
Subcellular fractions containing 150µg of protein were incubated with assay buffer (50 mM
Tris-HCl, pH 7.4 10 mM MgSO4 and 0.5 mM EDTA) containing 3 nM 3H-8-OH-DPAT in a
total volume of 0.5ml at room temperature for one hour. The non-specific binding was
defined in the presence of 10µM 5-HT. The total and non-specific binding of each fraction
were measured in triplicate and duplicate, respectively. The reaction solution was then
filtered with GF/B filter paper and washed three times with 5 ml of 50 mM Tris-HCl, pH7.4.
The radioactivity of the filter paper was counted in 5 ml of scintillation solution. The
specific binding was calculated by subtracting the mean of non-specific binding from the
mean of total binding.
Immunoprecipitation
Immunoprecipitation was conducted using 200–500 µg protein of the brain tissue
preparation or fractions in total volume of 500 µl IP buffer (50 mM Tris, pH 7.4, 10 mM
EGTA, 100 mM NaCl, 0.5% Triton X-100, containing 20 mM NEM, 1:100 dilution of
protease inhibitor cocktail and phosphatase inhibitor cocktails). After preabsorption of
endogenous IgG with 25µl pre-washed agarose-protein G beads (Invitrogen, CA). The
protein was incubated with antibody, as listed in Table 1, at 4°C, overnight with nuitating.
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As a control, the same amount of IgG made in the same animal as the primary antibody was
added into another tube containing same amount tissue. The solution was then incubated
with 50µl pre-washed agarose-protein G beads for 2 hours at 4°C with nuitating. After
centrifugation at 1000 × g, 4°C for 3 min, the supernatant was decanted. The beads were
then washed with 0.5 ml IP buffer followed by centrifugation at 1000xg, 4°C for 3 min.
After washing three times, 25 µl PAGE sample buffer (1.3X) was added and incubated at
95°C for 5 min to elute bound proteins. The eluate (～35–40µl) from each
immunoprecipitation reaction was resolved in SDS-PAGE gels to identify the proteins.
Immunoblot assay
was conducted as described in our previous publication(Creech et al., 2012). Briefly,
samples were resolved in the SDS-PAGE gel (12% Acrylamide, Acrylamide: bis-acrylamide
= 30: 0.2). After transferring the protein to PVDF membrane, the membrane was then
incubated with 5% non-fat dry milk for one hour, followed by incubating with primary
antibody (Table 1) overnight at 4°C. After washing with TBS containing 1% Tween 20 three
times, the membranes were incubated with HRP-conjugated secondary antibody for 1 hour
at room temperature. The protein bands were then detected using chemiluminescent
detection. The image was captured using the Chemidoc XRS+ Image System and analyzed
using the Image Lab program (Bio-Rad laboratories, Hercules, CA).
Data analysis and statistics
All data were analyzed by analysis of variance (ANOVA) using StatView (Abacus Concepts
Inc., Berkeley, CA), unless otherwise mentioned. If a significant difference was detected, a
Student-Newman-Keuls post-hoc test was used to evaluate differences between individual
groups.
Results
Characterization of sumoylated 5-HT1A-Rs
Using immunoprecipitation with a SUMO1 antibody followed by immunoblotting with a 5-
HT1A-R antibody (characterized previously(Li et al., 2012)), we detected a ～55 KD band in
the membrane fraction, but not in the cytosolic fraction of rat cortex, suggesting SUMO1
conjugation to 5-HT1A-Rs in the membrane (Fig.1a). To verify the sumoylation of 5-HT1A-
Rs, we immunoprecipitated 5-HT1A-Rs from a cortical membrane preparation with a rabbit-
anti-5-HT1A-R antibody. A SUMO1-5-HT1A-R band at 55 kD was detected by a rabbit-anti-
SUMO1 antibody; a 5-HT1A-R antibody was used to further confirm the identity of the
55kD band (Fig.1b). In another experiment, we compared the sumoylated 5-HT1A-Rs from
cortical tissue in the presence or absence of NEM, an irreversible cysteine peptidase
inhibitor that inhibits sentrin/SUMO-specific proteases (SENPs), the protease responsible
for de-sumoylation of proteins. Without NEM, the amount of 5-HT1A-R precipitated by the
SUMO1 antibody was significantly reduced (Fig.1c), confirming that the SUMO1 antibody-
precipitated 5-HT1A-Rs are sumoylated. On the other hand, protease inhibitors did not
prevent the de-sumoylation of SUMO1from 5-HT1A-Rs . Instead, without protease inhibitor,
a ～30 kD mass band of 5-HT1A-R was increased (Fig.1c), suggesting that the 30 kD band
detected by the 5-HT1A-R antibody could be degraded 5-HT1A-R. To rule out the possibility
that the SUMO1 antibody cross-reacted with ubiquitin, we blotted the samples
immunoprecipitated with the SUMO-1 antibody with an ubiquitin antibody. No band was
detected in either the frontal cortex or hypothalamic samples (Fig.1d), although the
SUMO1-5HT1A-R and several ubiquitin proteins were detected in the SUMO1-
immunoprecipitated and input samples, respectively.
Li and Muma Page 6













To determine which brain regions contain sumoylated 5-HT1A-R, we examined numerous
brain regions that express 5-HT1A-Rs, including the frontal cortex, cortex, hippocampus,
hypothalamus and midbrain. Since 5-HT1A-Rs in the dorsal raphe are autoreceptors that are
located in the 5-HT neurons, we also measured sumoylated 5-HT1A-Rs in the dorsal raphe.
Using immunoprecipitation with a SUMO1 antibody followed by immunoblotting with a 5-
HT1A-R antibody, we found that the sumoylated 5-HT1A-Rs existed in all of the brain
regions examined (Fig.1e). Most of brain regions contained comparable amounts of
sumoylated 5-HT1A-Rs, except the midbrain in which sumoylated 5-HT1A-Rs were less
abundant than in other brain regions (Fig.1e).
Pre-treatment with estradiol (EB) for 2 days potentiates the (+)8-hydroxy-2-
dipropylaminotetralin (8-OH-DPAT)-induced increase in sumoylation of 5-HT1A-R in rat
hypothalamus
To determine whether the sumoylation of 5-HT1A-R is related to the activity of 5-HT1A-Rs,
we determined the effects of repeated treatment with EB and/or fluoxetine and acute
injection of 8-OH-DPAT on sumoylation of 5-HT1A-R. Our previous studies demonstrated
that a combined injection of EB and fluoxetine for 2 days produced a rapid desensitization
of 5-HT1A-Rs relative to fluoxetine alone as measured by hormonal responses to 5-HT1A-R
agonist, 8-OH-DPAT(Li et al., 2012). In the present study, we determined whether
sumoylation of 5-HT1A-R is related to EB facilitation of fluoxetineinduced desensitization
of 5-HT1A-Rs. To quantify the SUMO1-5-HT1A-Rs, we first produced a protein
concentration curve to determine the linear range of immunoprecipitation of SUMO1-5-
HT1A-Rs. Cortex membrane preparations containing 50, 100, 200, 300 and 400 µg protein
were used for immunoprecipitation with SUMO1 antibody followed by immunoblotting
with 5-HT1A-R antibody. As Fig 2a shows, the SUMO1-5-HT1A-R levels detected were
linearly correlated to the protein concentration in the range between 100–400 µg of protein.
Based on this study, we used 200–300 µg of protein in subsequent experiments.
To determine the effects of treatment with EB and /or fluoxetine for 2 days and acute
injection of 8-OH-DPAT on the sumoylation of 5-HT1A-R, the hypothalamic membrane
preparations from ovariectomized female rats treated with EB and /or fluoxetine for 2 days
and then challenged with 8-OH-DPAT were used to determine SUMO1-5-HT1A-R. Our
results showed that acute treatment with 8-OH-DPAT significantly increased SUMO1-5-
HT1A-Rs in the hypothalamus (Fig.2b). Although no significant difference was detected
among groups treated with EB and/or fluoxetine in saline-challenged rats, treatment with EB
and EB+fluoxetine, but not fluoxetine alone, produced a significant increase in the
sumoylated 5-HT1A-Rs in 8-OH-DPAT-challenged rats (Fig.2b, three-way ANOVA: main
effect of fluoxetine F(1,39)= 0.004, P=0.95; main effect of EB: F(1,39)= 12.64, P=0.001; main
effect of 8-OH-DPAT: F(1,39)= 214.76, P<0.001; interaction between fluoxetine X EB:
F(1,39)=0.335, P=0.56; interaction between fluoxetine × 8-OH-DPAT: F(1,39)= 0.01, P=0.91;
interaction between EB × 8-OH-DPAT F(1,39)= 7.77 P=0.0082; and interaction of fluoxetine
X EB X 8-OH-DPAT: F(1,39)=0.005, P=0.94). These data suggest that pre-treatment with
EB potentiates the 8-OH-DPAT-induced increase in the sumoylation of 5-HT1A-Rs.
Small proportion of sumoylated 5-HT1A-Rs exists in the DRM, but is not co-localize with
Gαz proteins and increases following stimulation with a 5-HT1A-R agonist
Like other GPCRs, active 5-HT1A-Rs are located in the DRM. To determine whether the
sumoylated 5-HT1A-Rs are located in the DRM, we isolated the DRM using a standard
protocol (Kumari and Francesconi, 2011), cold Triton X-100 treatment followed by sucrose
gradient centrifugation. As shown in figure 3a, an opaque DRM band was observed at
intersection of the 5% and 30% sucrose solutions, while another cloudy band was observed
at the intersection between the 30% and 40% sucrose solutions. The DRM was located in
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fractions 2–4 as verified by flotillin-1, a DRM marker. Similar to our previous results, we
demonstrated that Gαz protein (～35 kd) was mainly located in the DRM (Li et al., 2012).
The majority of sumoylated 5-HT1A-Rs was not located in the DRM but in the Triton X-100
soluble fractions. On the other hand, a small proportion of SUMO1-5-HT1A-Rs were
detected in the DRM fractions (Fig.3b, fractions 2–4). However, compared to flotillin-1 and
Gαz proteins, the distribution of the SUMO1-5-HT1A-Rs was shifted to the right, suggesting
that sumoylated 5-HT1A-Rs do not couple to G proteins. More importantly, acute treatment
with 8-OH-DPAT increased the SUMO1-5-HT1A-Rs in the DRM fractions (Fig.3b and 3c,
Paired t test between saline and 8–OH-DPAT treatment in each experiment: t= −12.22,
P=0.0066, n=4). Together, these data suggest that sumoylation may be related to the
internalization of 5-HT1A-R.
Subcellular distribution of sumoylated 5-HT1A-Rs
To further determine the subcellular location of sumoylated 5-HT1A-Rs, we conducted a
discontinuous gradient centrifugation with 7.5–30% iodixanol in the cortex preparation. The
subcellular organelles located in the fractions collected from the gradient centrifugation
were verified by immunoblotting with several organelle markers as shown in Figure 4A.
Several bands of 5-HT1A-Rs were detected on immunoblots. The distribution of these
different molecular mass 5-HT1A-Rs varied. In the plasma membrane, the 5-HT1A-Rs with
～37–40 kD molecular mass were detected, which is the predicted size of 5-HT1A-Rs based
on the amino acid sequence. On the other hand, the antibody detected a small size band in
the cytosolic fraction, which could be degraded 5-HT1A-R. The most abundant 5-HT1A-R
detected by the immunoblot was a 55 kD mass band. The distribution of this band was
similar to the sumoylated 5-HT1A-Rs and was predominantly co-localized with TGN 38, a
marker for the TGN, and calreticulin, a marker for the ER (Fig.4A). Similar to the
observation from the DRM preparation, a small proportion of SUMO1-5-HT1A-Rs were
distributed in the plasma membrane fractions that were identified by Na+/K+ ATPase,
flotillin-1 and Gαz protein. On the other hand, no SUMO1-5HT1A-R was detected in the
fractions containing endosomal protein (as marked by early endosome antigen 1 (EEA 1))
and cytosol (as marked by lactate dehydroxylase (LDH)). Although the distribution of the
lysosome marker, LAMP 1, was close to that of SUMO1-5-HT1A-Rs, they did not overlap.
To further confirm that the location of sumoylated 5-HT1A-Rs in the TGN and ER was not
due to contamination with the plasma membrane, we conducted a digitonininduced density
shift study. Treatment with digitonin shifts membrane compartments containing high
cholesterol, such as the plasma membrane and endosome, to a higher density. On the other
hand, the compartments containing low concentrations of cholesterol, such as Golgi and ER,
do not shift or only minimally shift with digitonin treatment. Thus, we hypothesized that if
SUMO1-5-HT1A-Rs were located in the TGN and/or ER, the digitonin treatment would not
shift or minimally shift the SUMO1-5-HT1A-R to a higher density. However, if the
SUMO1-5-HT1A-R are in the plasma membrane or endosome, digitonin treatment should
shift it to higher density. Subcellular fractions of the hippocampus were obtained by
discontinuous gradient centrifugation with 7.5–30% iodixanol (Fig.4Ba and 4Bb). The
subcellular fractions containing plasma membrane (fraction 13 and 14, marked by Na+/K+
ATPase) and ER (fraction 18 and 19, marked by the peak of the calnexin fractions) were
treated with digitonin or vehicle followed by a second discontinuous gradient centrifugation
with 17.5 −35% (for plasma membrane fractions) and 25–50% (for ER fractions) iodixanal,
respectively (Fig.4Bc). The results showed that treatment with digitonin shifted the
distributions of SUMO1-5-HT1A-Rs and Na+/K+ ATPase in the plasma membrane fractions
to a higher density (Fig.4Bc and 4Bd). On the other hand, only a very small shift was
observed in the distributions of SUMO1-5-HT1A-R and calnexin in the ER fraction (Fig.
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4Bc and 4Be). These results suggest that sumoylated 5-HT1A-Rs are mainly located in the
TGN and ER, whereas relatively low amounts are located in the plasma membrane.
SUMO1-5-HT1A-R has low affinity for 5-HT1A-R agonist
We next conducted a 3H-8-OH-DPAT binding assay in the subcellular fractions to
determine whether the sumoylated 5-HT1A-Rs are functional. Subcellular fractions of the
cortex were obtained from discontinuous gradient centrifugation with 10–40% iodixanal and
were collected as 1 ml per fraction. Each fraction was divided into two. One half was used
for 3H-8-OH-DPAT binding and another half was used for immunoprecipitation of
SUMO1-5-HT1A-Rs. The results showed that 3H-8-OH-DPAT binding distributed in
fractions 2 to 6 with a peak at fraction 4, which correlated with the plasma membrane
makers, Na+/K+ ATPase and flotillin, and the 35 kD Gαz proteins (Fig.5). On the other
hand, SUMO1-5-HT1A-Rs are distributed from fraction 4 to 9 with a peak at fraction 6,
which is similar to LMAN1 (lectin mannose-binding 1, ERGIC 53), the marker for the
ERGIC (Fig.5). Although the distribution curve of 3H-8-OH-DPAT binding overlapped with
that of SUMO1-5-HT1A-R, fractions 4 and 5 have high 3H-8-OH-DPAT binding but very
low levels of SUMO1-5-HT1A-Rs. On the other hand, fraction 6 has high levels of
SUMO1-5-HT1A-Rs, but little 3H-8-OH-DPAT binding (Fig.5). These data suggest that
SUMO1-5-HT1A-Rs have low affinity to 3H-8-OH-DPAT and thus, are not active receptors.
It is interesting that SUMO-conjugating enzyme (ubc 9), a key enzyme involved in
sumoylation, was co-localized with plasma membrane markers, Na+/K+ ATPase and
flotillin, in the subcellular fractions (Fig.5). Similarly, a small portion of ubc 9 was detected
in the DRM in the Triton X-100 treated sucrose fractions (Fig.3B). These data suggest that
sumoylation can occur in the DRM, however, only a small fraction of sumoylated receptor is
actually retained in this region of the plasma membrane.
Discussion
Protein sumoylation is an important post-translational modification that has recently gained
attention. Although the vast majority of studies on sumoylation focus on the regulation of
nuclear proteins, recent studies have revealed that sumoylation can also play an important
role in regulating the function of extra-nuclear proteins (Scheschonka et al., 2007). To date,
only a few sumoylated GPCRs have been identified and the effect of sumoylation varies
among these GPCRs (Scheschonka et al., 2007; Wilkinson et al., 2010). In the present study,
we report, for the first time, that 5-HT1A-Rs can be sumoylated by SUMO-1 proteins. Acute
treatment with the 5-HT1A-R agonist, 8-OH-DPAT increases the sumoylated 5-HT1A-Rs in
the hypothalamus of rats. This increase is potentiated by 2 days of treatment with estradiol,
which produces a partial desensitization of 5-HT1A-Rs (Li et al., 2012). The majority of
sumoylated 5-HT1A-R is Triton X-100 soluble and co-localizes with TGN, ERGIC and the
ER markers. On the other hand, a small proportion of SUMO1-5-HT1A-Rs was detected in
the DRM. However, they are not co-localized with Gαz proteins that are known to couple to
active 5-HT1A-Rs. The SUMO1-5-HT1A-Rs have minimal 5-HT1A-R agonist binding,
further supporting that they are inactive receptors. Furthermore, acute stimulation of 5-
HT1A-Rs increases the SUMO1-5-HT1A-Rs in DRM. These data suggest that sumoylation
of 5-HT1A-Rs inactivates 5-HT1A-R, which may be related to the desensitization of 5-HT1A-
Rs.
5-HT1A-R is one of the most well studied serotonin receptors. Multiple lines of evidence
demonstrate that 5-HT1A-Rs play an important role in mood regulation and may be involved
in the etiology of affective disorders. SSRI-induced desensitization of 5-HT1A-Rs may be
necessary for SSRI-mediated therapeutic effects on affective disorders. Studies have
demonstrated that treatment with estradiol produces a partial desensitization of 5-HT1A-Rs
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several brain regions (Bethea et al., 2000; Creech et al., 2012; Mize et al., 2003).
Furthermore, estradiol-treatment for 2 days facilitates the SSRI-induced desensitization on
5-HT1A-Rs (Li et al., 2012). Therefore, it is important to understand the mechanisms
underlying estradiol-induced desensitization of 5-HT1A-Rs. In the present study, we found
that estradiol potentiates the 8-OH-DPAT-induced increase in sumoylation of 5-HT1A-Rs.
Since SUMO1-5-HT1A-Rs are inactive, the increase in the SUMO1-5-HT1A-Rs may be
related to the desensitization of the receptors. A G-protein coupled estrogen receptor, GPER,
co-localizes with 5-HT1A-Rs in the DRM and is necessary and sufficient for estradiol-
induced partial desensitization of 5-HT1A-R signaling (McAllister et al., 2012; Xu et al.,
2009). Hence, it is possible that stimulation of the GPER signaling pathways by estradiol
activates the sumoylation system, which in turn facilitates the sumoylation of 5-HT1A-Rs
induced by 8-OH-DPAT.
EB negatively regulates a number of other GPCRs including mu-opioid, GABAB and CB1
receptors (Kellert et al., 2009; Kelly et al., 1992; Lagrange et al., 1996; Peckham et al.,
2011). Further studies are needed to determine if receptor sumoylation is the mechanism by
which EB reduces signaling via these GPCRs, however sumoylation of µ-opioid and
GABAB receptors has not been reported. Although CB1 receptors are sumoylated, agonist
stimulation decreases sumoylation of CB1 receptors and results in internalization of the
receptors (Gowran et al., 2009).. The results on CB1 receptors suggest that the effect of EB
on CB1 receptors is not mediated via increased sumoylation of the receptors.
The DRM of plasma membrane, including lipid raft and caveolae, is a planar domain in the
membrane containing high concentrations of cholesterol and glycosphingolipid (Allen et al.,
2007; Chini and Parenti, 2004). The DRM plays a role in assembling components of the
GPCR signaling pathways, physically bringing together these components for GPCR
signaling. G-protein coupled 5-HT1A-Rs are located in the DRM (Pucadyil and
Chattopadhyay, 2004). In the present study, we found a small proportion of SUMO1-5-
HT1A-Rs is located in the DRM, which is unlikely to be contaminated by high density
fractions. This is clearly demonstrated in Triton X-100-treated sucrose samples in which
SUMO1-5-HT1A-Rs in the DRM are located at fractions 3 and 4 whereas the SUMO1-5-
HT1A-Rs in the Triton X-100 soluble fractions appear in the fraction 8–12 (Fig.3).
Furthermore, the SUMO1-5-HT1A-Rs in the plasma membrane are shifted by digitonin-
treatment, while the SUMO1-5-HT1A-Rs in the ER fractions are not shifted by digitonin
(Fig. 4B). Since 5-HT1A-Rs are coupled to Gαz proteins, one can expect that active 5-HT1A-
Rs, i.e. G protein-coupled receptors, should be co-localized with Gαz proteins. However, the
distribution of the SUMO1-5-HT1A-Rs in the DRM is shifted to the right from that of Gαz
proteins, suggesting that SUMO1-5-HT1A-Rs are not coupled to Gαz proteins. This is
further supported by the observation that 5-HT1A-R agonist binding to SUMO1-5-HT1A-Rs
is minimal. Together with the observation that treatment with 8-OH-DPAT significantly
increased sumoylated 5-HT1A-Rs in the DRM (Fig.3), these data suggest that SUMO1-5-
HT1A-Rs are inactive and that may be related to agonist-induced internalization of the
receptors. This observation is similar to recent findings that stimulation with kainate
receptor agonist induces sumoylation of a kainate receptor subunit, GluK2, and triggers the
internalization of GluK2-containing kainate receptors (Chamberlain et al., 2012; Konopacki
et al., 2011).
Studies have demonstrated that palmitoylation is required for 5-HT1A-Rs to be transported
to the DRM of plasma membrane, where they couple with Gαi proteins and become active
(Kobe et al., 2008; Papoucheva et al., 2004; Renner et al., 2007). Our present results suggest
that sumoylation of 5-HT1A-Rs may be related to the internalization of the receptors, i.e.,
removal of the receptors from DRM. Thus, we can speculate that palmitoylation of 5-HT1A-
Rs promote their translocation to the DRM in the plasma membrane, where they couple to G
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proteins and thus, are able to bind with agonists and activate 5-HT1A-R signaling pathways.
After stimulation by agonists, the 5-HT1A-Rs dissociate from G proteins and are
sumoylated. Sumoylation may trigger the removal of 5-HT1A-Rs from the DRM. A similar
case was reported by Schmidt et al (Schmidt et al., 2009). Palmitoylation of Bright, a B-cell
restricted transcription factor, promotes the factor localizing into the DRM. After B-cell
antigen receptor binds to ligand, Bright is sumoylated and then removed from the DRM
(Schmidt et al., 2009). Our present results showed that a key enzyme in sumoylation, ubc 9,
is located in the DRM. Furthermore, results from others and our studies demonstrated that
several DRM proteins, such as caveolin-3, arrestin-3 and Gαz in the DRM can be
sumoylated (Fuhs and Insel, 2011; Li et al., 2012; Wyatt et al., 2011). These data suggest
that sumoylation can occur in DRM. Further studies are required to verify this hypothesis.
Our present results show that the majority of sumoylated 5-HT1A-Rs are Triton X-100
soluble and co-localize with TGN, ERGIC and ER markers. Recent studies showed that 5-
HT1A-Rs are not only located on the plasma membrane, but also in intra-cellular organelles
(Cheng et al., 2011; Xu et al., 2009) and many GPCRs accumulate in intracellular
compartments, such as TGN, Golgi complex and ER (Achour et al., 2008). Currently, we do
not know the function of these intracellular SUMO1-5-HT1A-Rs and since we cannot
individually isolate the TGN, ERGIC and ER, we do not know which of these organelles
contain sumoylated 5-HT1A-Rs. If the sumoylated 5-HT1A-Rs are located in the TGN, we
could speculate that the SUMO1-5-HT1A-Rs come from DRM after agonist stimulation and
are stored in TGN for either recycling or lysosomal degradation. However, as recent studies
have revealed that some GPCRs are translocated to TGN through the endosome, in response
to agonist stimulation, it is not likely that 5-HT1A-Rs are internalized from the DRM to the
TGN since, we did not detect the SUMO1-5-HT1A-Rs in the subcellular fractions labeled
with the endosomal marker. On the other hand, if the SUMO1-5-HT1A-Rs are located in the
ER or ERGIC, sumoylation could be related to the regulation in maturation and export of 5-
HT1A-R from the ER to the plasma membrane. GPCRs are synthesized by the ribosome in
the ER and then, undergo maturation processes, including insertion in the membrane and
folding to their native conformation. Matured GPCRs are then packaged into vesicles and
transported to the Golgi complex, ERGIC, cis-Golgi and TGN and finally, are sorted into the
plasma membrane (Achour et al., 2008). Thus, we can speculate that the SUMO1-5-HT1A-
Rs could serve as “reserved” 5-HT1A-Rs that are stored in the ER. Activation of 5-HT1A-R
signaling pathways trigger sumoylation of newly synthesized 5-HT1A-Rs in the ER, which
prevents export of the receptors and results in retention of the receptors in the ER. If this is
the case, the sumoylation of 5-HT1A-R regulates the export trafficking of the receptor. This
hypothesis can explain our observation that acute administration of 5-HT1A-R agonist, 8-
OH-DPAT, significantly increased sumoylated 5-HT1A-Rs. Several proteins have been
reported to be sumoylated in the ER (Felberbaum et al., 2012; Majumdar et al., 2011; Yip et
al., 2012). For example, sumoylation of transcription factor X box-binding protein 1(XBP1)
in the ER results in accumulation of the protein in the ER, reduction of its activity and
increases in ER stress responses (Jiang et al., 2012). These data suggest that sumoylation in
the ER serves as a mechanism to regulate the maturation of proteins, including protein
folding and transport. However, to date, no data have been reported regarding the
sumoylation of GPCRs in the ER, although one study found that CB1 receptors are
sumoylated tonically and desumoylated up on agonist stimulation (Gowran et al., 2009).
In conclusion, the present results demonstrate, for the first time, that 5-HT1A-Rs can be
sumoylated. Our results strongly suggest that the sumoylated 5-HT1A-Rs are inactive.
Sumoylation may be related to the regulation of 5-HT1A-R trafficking, such as agonist-
induced internalization and/or retaining 5-HT1A-R in the ER. Similar to the effects of
sumoylation of other plasma membrane proteins and GPCRs, sumoylation of 5-HT1A-Rs
may serve as a negative control mechanism contributing to the desensitization of the
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receptors in response to agonist stimulation. Indeed, we also found that EB treatment which
causes desensitization of 5-HT1A-R signaling also increased sumoylation of 5-HT1A-Rs.
Since EB and 5-HT1A-Rs play an important role in mood regulation, the present results will
have a significant impact on understanding the regulation of 5-HT1A-Rs and thus, the
development of new approaches to treat affective disorders.
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Figure 1. Characterization of SUMO1-5-HT1A-Rs in rat brain
a. SUMO1-5-HT1A-Rs (55 kD) are observed in the membrane, but not the cytosolic
fractions of rat cortex. Immunoprecipitation (IP) with mouse-anti-SUMO1 followed by
immunoblotting (IB) with rabbit-anti-5-HT1A-R. b. Confirming the SUMO1-5-HT1A-Rs
using 5-HT1A-R antibody for immunoprecipitation followed by immunoblotting with rabbit-
anti-SUMO1 antibody in the rat cortex homogenates. Left blot: immunoprecipitation with a
rabbit-anti-5-HT1A antibody followed by immunoblotting with a rabbit anti-SUMO1
antibody (detected with Clean-blot (Thermo Scientific Inc, Rockford IL)); Middle blot:
immunoprecipitation with a mouse-anti-SUMO1 antibody followed by immunoblotting with
Li and Muma Page 15













a rabbit-anti-5-HT1A-R antibody; and right blot: re-immunoblotting the blot in the left panel
with a rabbit-anti-5-HT1A receptor antibody. AB control: immunoprecipitation without
sample as a bead control; IgG IP: immunoprecipitation with same concentration of IgG
(same species as primary antibody) as an IP control. c. SUMO1-5-HT1A-Rs are reduced in
the absence of NEM, an inhibitor of SENPs, the peptidase for de-sumoylation of proteins.
SUMO1-5-HT1A-Rs were compared in the presence and absence of NEM and protease
inhibitors (Prot-I). d. The SUMO1 antibody does not pull-down ubiquitin-conjugated
proteins. Hypothalamus and frontal cortex preparations were immunoprecipitated with
SUMO1 antibody followed by immunoblotting with an anti-ubiquitin antibody. As a control,
left two lanes contain samples immunoprecipitated with the SUMO1 antibody followed by
immunoblotting for 5-HT1A-R. e. SUMO1-5-HT1A-Rs are distributed in the brain regions
that express 5-HT1A-Rs. Input: sample without immunoprecipitation; Amy: amygdala; DR:
dorsal raphe; FCX: Frontal cortex; Hippo: hippocampus; Hypo: hypothalamus; MB:
midbrain.
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Figure 2. Treatment with estradiol (EB) for 2 days potentiates the 8-OH-DPAT-induced increase
in sumoylation of 5-HT1A-Rs
a. Protein concentration curve for quantification of SUMO1-5-HT1A-Rs. 50–400 µg protein
of cortex preparation was immunoprecipitated with a mouse-anti-SUMO1antibody followed
by immunoblotting with a rabbit-anti-5-HT1A-R antibody. IgG: immunoprecipitation with
the same amount of mouse IgG instead of a SUMO1 antibody. b. Effect of EB and/or
fluoxetine treatment for 2 days on 8-OH-DPAT-induced increase in SUMO1-5-HT1A-Rs.
SUMO1-5-HT1A-Rs were measured in the hypothalamic membrane preparation of rats pre-
treated with EB and /or fluoxetine for 2 days and challenged with saline or 8-OH-DPAT 15
min before decapitation. The SUMO1-5-HT1A-R levels were normalized to SUMO1-β-actin
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and then calculated as percent of the oil/saline/saline-treated samples in the same blot. The
data are presented as the mean ± SEM of 4–6 rats. * indicates significant difference from
saline-challenged rats with same pre-treatment; # indicates significantly different from
saline/oil pre-treated group with same challenge.
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Figure 3. Distribution of SUMO1-5-HT1A-Rs in sucrose gradient fractions of Triton X-100-
treated cortex preparation
DRM of cortex was isolated as described in the online methods. a. A picture of sucrose
gradient centrifugation sample showing bands at the intersection between 5% and 30%
sucrose and the intersection between 30% and 40% sucrose. b. The distribution of
SUMO1-5-HT1A-R, 5-HT1A-Rs, Gαz protein, ubc 9 and plasma membrane markers in the
sucrose fractions of Triton X-100-treated cortex. SUMO1-5-HT1A-R was determined using
immunoprecipitation with a SUMO1 antibody followed by immunoblotting with a 5-HT1A-
R antibody using cortex homogenates from rats injected with saline or 8-OH-DPAT 15 min
before decapitation. The distribution of 5-HT1A-Rs, Gαz proteins, ubc9 (key enzyme for
sumoylation), flotillin 1(DRM marker) and Na+/K+ ATPase (plasma membrane marker)
were determined using immunoblots with 10 µg protein/fraction. The fractions in the blot
correlate to the fractions indicated in Fig 3a. IgG: mouse IgG was used for
immunoprecipitation instead of a SUMO1 antibody. c. Acute treatment with 8-OH-DPAT
significantly increases SUMO1-5-HT1A-Rs in the DRM. The integrated optic density (IOD)
of the band of SUMO1-5-HT1A-R (total IOD – background IOD) was measured in fractions
3–7. Then, the area under the curve (AUC) of the IOD of fractions 3–7 was determined
using Sigma Plot (Systat Software Inc, San Jose, CA). The percent of ACU for saline-treated
rats in same experiment was then calculated. The data were presented as mean ± SEM of %
ACU of saline-treated rats from 4 separate experiments. * indicates significantly different
from saline-treated rats, P< 0.05 by a paired t-test between saline and 8-OH-DPAT-treated
samples in each experiment.
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Figure 4. Distribution of SUMO1-5-HT1A-Rs in the subcellular fractions from discontinuous
iodixanol gradient centrifugation
A. Comparison of the distribution of SUMO1-5-HT1A-Rs with the distribution of 5-HT1A-
Rs, Gαz proteins and markers of subcellular organelles in the rat cortex. SUMO1-5-HT1A-R
levels were determined using immunoprecipitation with a SUMO1 antibody followed by
immunoblotting with a 5-HT1A-R antibody. The distribution of 5-HT1A-Rs, Gαz proteins
and markers of organelles were determined using immunoblots with 10 µg of protein. B.
Digitonin-induced shift of subcellular fractions in the hippocampus. a. Picture of
discontinuous iodixanol gradient centrifugation showing the protein bands relative to the
fractions collected. b. subcellular fractions of the hippocampus separated by discontinuous
iodixanol gradient centrifugation. The boxed fractions (13 & 14) and (18 & 19) were pooled
and further used for the digitonin-induced shift study. c. Example of discontinuous iodixanol
gradient centrifugation of digitonin-treated hippocampal subcellular fractions, showing that
digitonin treatment induced a shift of protein bands to the higher density in subcellular
fractions 13 & 14 (plasma membrane), but not in fractions 18 & 19. d and e. Effects of
digitonin treatment on the distribution of SUMO1-5-HT1A-Rs, 5-HT1A-Rs and subcellular
markers, Na+/K+ ATPase (plasma membrane marker) and calnexin (ER marker) in
digitonin-treated subcellular fractions of plasma membrane (fractions 13 & 14) and ER
fractions (fraction 18 & 19), respectively. SUMO1-5-HT1A-R was determined using
immunoprecipitation with a SUMO1 antibody followed by immunoblotting with a 5-HT1A
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receptor antibody. The distribution of 5-HT1A-R, Na+/K+ ATPase and calnexin were
determined using immunoblots with 5 µg protein. The IOD of the bands of SUMO1-5-
HT1A-R, 5-HT1A-R, Na+/K+ ATPase and calnexin was measured and presented as IOD.
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Figure 5. Comparison of the distribution of 3H-8-OH-DPAT binding with that of SUMO1-5-
HT1A-R
Subcellular fractions (1ml/fraction) were generated by discontinuous gradient centrifugation
with 10%–40% iodixanol. Each fraction was divided into two parts, one for the 3H-8-OH-
DPAT binding assay and one for immunoprecipitation for SUMO1 and immunoblot for 5-
HT1A-R, Gαz protein, ubc9 and markers of subcellular organelles. Top graph compares the
profiles of the distribution of 3H-8-OH-DPAT binding (solid line) with that of SUMO1-5-
HT1A-R (dashed line), in which IOD of the blot was measured and calculated as % of the
peak fraction. Bottom panel shows immunoblots of 5-HT1A-R, Gαz protein, ubc 9 and
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markers of subcellular organelles. The SUMO1-5-HT1A-Rs were determined by
immunoprecipitation with SUMO1 antibody followed by 5-HT1A-R.
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Table 1
Antibodies used for immunoprecipitation and immunoblots
Antibodies IP Immunoblot Source
Mouse-anti-SUMO-1 (D-11) 4 µg Santa Cruz #sc-5308
Rabbit-anti-SUMO-1 1:1,000 Enzo #BML-PW0505
Rabbit-anti-Gαz (1–20) 4 µg 1:2,000 Santa Cruz #sc-388
Rabbit-anti-5HT1A receptor 15 µg 1:500 Gift from Dr. Scrogin
Mouse-anti-Flotillin-1 1:2,000 BD #610820
Rabbit-anti-Ubiquitin 1:1,000 DAKO#Z0458
Goat-anti-ubc9 1:200 Santa Cruz #sc-5231
Mouse-anti-Na+/K+ ATPase α1 1:2,000 Santa Cruz #sc-21712
Rabbit-anti-calreticulin 1:2,000 Abcam #Ab4
Rabbit-anti-calnexin 1:10,000 (1 hour) GenScript #A01240
Rabbit-anti-LMAN1 1:500 Epitomic #T3357
Rabbit-anti-TGN38 (M290)* 1:1,000 Santa Cruz #sc-33784
HRP conjugated LDH 1:4,000 Abcam #Ab7639-1
Goat-anti-EEA1 (C-15) 1:1,000 Santa Cruz #sc-6414
Goat-anti-Lamp1 (C20) 1:200 Santa Cruz #sc-8098
Mouse-anti-β-actin (C4) 1:20,000 (30–60 min) MP #08691001
Abcam: Abcam Inc. Cambridge, MA; BD: BD Biosciences San Jose, CA; DAKO: DAKO A/S, Denmark; Enzo: Enzo Life Sciences Inc.
Farmingdale, NY; Epitomics: Epitomics Inc. Burlingame, CA; MP: MP Biomedicals, LLC, Solon, OH; Novus: Novus Biologicals Inc., Littleton,
Co; Dr. Scrogin: Karie E Scrogin at Loyola University Chicago; Santa Cruz: Santa Cruz Biotechnology Inc., Santa Cruz, CA.
*
Wash with 2% milk in 1% Tween 20 TBS.
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